Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Sleep, Addiction, and Metabolic Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HCRTR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | HCRTR1 Lentivirus Premade Particles. Full-length GPCR for stable cell line generation. HEK293T packaged, titer >1x10^8 TU/ml. Sequence Verified. | View HCRTR1 Products |
| Antigen (Surrogate Peptides) | HCRTR1 Extracellular Loop Peptides. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified for antibody screening. | View HCRTR1 Products |
| Benchmark Antibody | Anti-HCRTR1 Biosimilar Antibody. Recombinant positive control for flow cytometry and binding assays. | View HCRTR1 Products |
| Validator | HCRTR1 siRNA Set. For knockdown validation and specificity confirmation in cellular assays. | View HCRTR1 Products |
| Counter-Screening | HCRTR2 (Orexin Receptor 2) Lentivirus. Crucial for OX1R vs OX2R selectivity (DORA vs SORA). | View HCRTR2 Products |
| Ligand Control | HCRT / Orexin-A Recombinant Protein. Native sequence, >95% purity. Suitable for binding competition assays. | View HCRT Products |
| Related Target: Reward Pathway | DRD2 (Dopamine Receptor D2). Critical for addiction mechanism studies; evaluate HCRTR1-DRD2 crosstalk. | View DRD2 Products |
| Related Target: Stress Axis | CRHR1 (Corticotropin Releasing Hormone Receptor 1). Synergistic with orexin system in anxiety and stress responses. | View CRHR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Stability & Internalization | Full-length ORF lentivirus with native membrane topology; HEK293-expressed for proper glycosylation; Suitable for calcium flux and receptor internalization assays. |
| Species Cross-Reactivity | Human/Cyno/Rat/Mouse HCRTR1 lentiviral vectors available; Sequence identity verified by NGS; Codon-optimized for mammalian expression. |
| HCRTR1 vs HCRTR2 Selectivity | Dual receptor panel (HCRTR1/HCRTR2) stable cell lines for counter-screening; Endotoxin <1EU/ug to prevent false signaling. |
| Lack of Controls & False Positives | Validated siRNA included for target specificity confirmation; Clinical benchmark antibodies available as positive controls; Sequence-verified clones for baseline normalization. |
Live HCRTR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HCRTR1-targeting therapeutics is intensifying, with major players shifting focus from dual orexin receptor antagonists (DORAs) to selective HCRTR1 modulators for addiction and neuropsychiatric indications. First-generation insomnia therapies (Suvorexant, Lemborexant, Daridorexant) have reached the clinic, while the next wave of R&D targets substance use disorders, anxiety, and metabolic syndrome through selective HCRTR1 blockade or biased signaling. As OX1R signaling dominates over OX2R in reward and stress pathways, the transition from sleep to psychiatric and metabolic indications is accelerating.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Dual Antagonist (DORA) | Merck, Eisai, Idorsia | Insomnia | Receptor Internalization Assay (Need full-length HCRTR1/HCRTR2 stable cells). |
| Selective HCRTR1 Antagonist (SORA) | Janssen, Takeda, Actelion, Minerva | Addiction, Anxiety, Panic Disorders | Selectivity Panel (HCRTR1 vs HCRTR2; Need species orthologs for translational studies). |
| Peptide Modulator | Takeda, Orexia, Academic/Start-up | Narcolepsy Type 1, Obesity | Calcium Flux Assay (Need high-expression stable cell lines with native conformation). |
| Bias Signaling Ligand | Emerging Biotech | Obesity / Metabolic Syndrome | Pathway-specific Reporter Assays (Gq vs Beta-arrestin). |